Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference23 articles.
1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002
2. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial;van Oers;Blood,2006
3. Rituximab in DLBCL: 6 years on;Cabanillas;Lancet Oncol,2011
4. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006
5. Importance of relative dose intensity in chemotherapy for diffuse large B-Cell lymphoma;Yamaguchi;J Clin Exp Hematop,2011
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Role of CT Radiomics Analysis in Predicting Overall Survival Following initial Chemotherapy for Diffuse Large B-cell Lymphoma;2024-04-19
2. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials;Leukemia & Lymphoma;2023-08-07
3. CLINICAL EFFICACY OF RITUXIMAB COMBINED WITH CHOP REGIMEN SEQUENTIAL OR NON-SEQUENTIAL LOCAL RADIOTHERAPY IN PATIENTS WITH STAGE III-IV DIFFUSE LARGE B-CELL LYMPHOMA;ACTA MEDICA MEDITERR;2023
4. Monoclonal Antibody and Targeted Toxin Therapy;Holland‐Frei Cancer Medicine;2022-10-21
5. Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma;Journal of Cancer Research and Clinical Oncology;2022-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3